# Bobby Reddy Jr.

> Bobby Reddy Jr. is an electrical engineer, scientist, and co-founder and CEO of Chicago-based Prenosis. After an early point-of-care device failed to find a market, he spent roughly two years listening to clinicians and patients inside a Champaign hospital, then refocused the company on understanding the complex biology of acute care. That patient, problem-first turn led to Sepsis ImmunoScore, granted FDA De Novo authorization in April 2024, followed by a Roche distribution collaboration, TIME recognition, a $20 million Series A, and a $20 million BARDA contract.

- **Role:** CEO & Co-Founder at Prenosis
- **Organizations:** Prenosis, University of Illinois Urbana-Champaign
- **Education:** B.S. in Computer Engineering and B.S. in Electrical Engineering, University of California, Irvine, M.S. in Electrical Engineering, University of California, Irvine, Ph.D. in Electrical Engineering, focused on biotech devices and algorithms, University of Illinois Urbana-Champaign
- **Known for:** Led Prenosis through FDA De Novo authorization of Sepsis ImmunoScore on April 2, 2024., Built Prenosis from a University of Illinois spinout into a Chicago biotechnology company with hospital, government, laboratory and diagnostics partnerships., Led the creation of a proprietary acute-care biobank and biomarker-linked clinical dataset containing more than 110,000 blood samples from more than 27,000 patients by 2025.

## Career timeline

- **2012** — While at the University of Illinois, Reddy and professor Rashid Bashir began combining their entrepreneurial interests around a point-of-care biomarker device.
- **2014** — Co-founded Prenosis with Rashid Bashir as a University of Illinois spinout.
- **2016-2017** — Prenosis received its first funding; while based at Carle Foundation Hospital, Reddy spent extensive time interviewing hospital staff and patients and redirected the company toward acute-care biology.
- **2023** — Served as principal investigator on a $2.54 million NIH SBIR Phase II award studying time-series biomarker and clinical data.
- **2024-04** — The FDA granted De Novo authorization for Prenosis's Sepsis ImmunoScore, an AI/ML software device that aids sepsis risk assessment.
- **2024-04** — Prenosis announced a commercial distribution collaboration with Roche for Sepsis ImmunoScore on the navify Algorithm Suite.
- **2024-10** — TIME named Sepsis ImmunoScore to its Best Inventions of 2024 list.
- **2025** — Reddy was named to the TIME100 Health list and recognized as a Chicago Titan 100 honoree; Prenosis received a Chicago Innovation Award.
- **2026-01** — Prenosis announced a $20 million Series A and a separate $20 million BARDA contract.
- **2026-04** — Illinois Grainger Engineering profiled Reddy's problem-first pivot and plans to expand Prenosis's platform beyond its initial commercial product.

## Achievements

- Led Prenosis through FDA De Novo authorization of Sepsis ImmunoScore on April 2, 2024.
- Built Prenosis from a University of Illinois spinout into a Chicago biotechnology company with hospital, government, laboratory and diagnostics partnerships.
- Led the creation of a proprietary acute-care biobank and biomarker-linked clinical dataset containing more than 110,000 blood samples from more than 27,000 patients by 2025.
- Secured a commercial distribution collaboration with Roche Diagnostics for Sepsis ImmunoScore.
- Named to the 2025 TIME100 Health list.
- Recognized as a 2025 Chicago Titan 100 honoree.
- Led Prenosis through a $20 million Series A financing and a separate $20 million BARDA contract announced in January 2026.
- Principal investigator on multiple publicly funded research projects, including a $2.54 million NIH SBIR Phase II award.

## Latest updates

- **2026-06** — Appeared on FINN Voices to discuss Prenosis's expansion beyond its first commercial solution and the use of biomarkers, clinical data and real-time integration in acute care.
- **2026-04** — Illinois Grainger Engineering published a profile of Reddy and Prenosis, including the planned 800-patient randomized trial and a broader precision-medicine clinical network.
- **2026-01** — Prenosis announced the completion of a $20 million Series A financing round and a $20 million BARDA contract.
- **2025-09** — Joined the AI in Chicago podcast for a detailed discussion of Prenosis's product pivot, clinical AI development, FDA authorization and Chicago's operating culture.
- **2025-05** — Named to the TIME100 Health 2025 list.

## Links

- Website: https://prenosis.com
- LinkedIn: https://www.linkedin.com/in/bobby-reddy-jr-233b1821
- Twitter/X: https://twitter.com/PrenosisInc

---

Profile page: https://yespress.io/bobby-reddy
Published by YesPress — https://yespress.io
Last updated: 2026-08-26